Last reviewed · How we verify
ACEI continuation
ACEI continuation refers to the ongoing use of angiotensin-converting enzyme inhibitors to block the conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction and lowering blood pressure.
ACEI continuation refers to the ongoing use of angiotensin-converting enzyme inhibitors to block the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction.
At a glance
| Generic name | ACEI continuation |
|---|---|
| Also known as | quinapril, Accupril, perindopril, Aceon, ramipril |
| Sponsor | University of Nebraska |
| Drug class | ACE inhibitor |
| Target | Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
ACE inhibitors work by inhibiting the angiotensin-converting enzyme, which is responsible for converting inactive angiotensin I into the potent vasoconstrictor angiotensin II. By blocking this conversion, ACEIs reduce peripheral vascular resistance, decrease blood pressure, and reduce the workload on the heart. This mechanism also leads to decreased aldosterone secretion, reducing sodium and water retention.
Approved indications
- Hypertension
- Heart failure
- Post-myocardial infarction
- Diabetic nephropathy
Common side effects
- Dry cough
- Dizziness
- Hyperkalemia
- Angioedema
- Fatigue
Key clinical trials
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Management of Angiotensin Inhibitors During the Perioperative Period (NA)
- ACEi ARB Withdrawal in CKD Patients (NA)
- Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery (PHASE4)
- Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With and Without COVID-19 (NA)
- Stopping ACE-inhibitors in COVID-19 (PHASE4)
- Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019 (NA)
- ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACEI continuation CI brief — competitive landscape report
- ACEI continuation updates RSS · CI watch RSS
- University of Nebraska portfolio CI